reports
BlackLine Acquires WiseLayer to Enhance its AI Capabilities
BlackLine Acquires WiseLayer to Enhance its AI Capabilities Acquisition Accelerates BlackLine's Vision for an AI-Powered Finance and Accounting Platform LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BL), the future-ready platform for the Office of the CFO, today announced it has acquired WiseLayer, a New York-based company that has pioneered a digital workforce of AI-powered agents to automate complex, judgment-based finance and accounting processes. Terms of the deal were not disclosed. This acquisition takes BlackLine’s industry-leading automation to the next level, empowe...
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at ...
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight abstracts at the ® (SABCS). The company will share the latest advances in the that support guideline-driven treatment decisions. Additionally, the company is presenting data on its , an ul...
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI ...
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health Actionable offering helps enable earlier, more personalized breast cancer interventions BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), and , today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens. The agreement brings together three leader...
BlackLine Issues Statement Regarding Shareholder Engagement
BlackLine Issues Statement Regarding Shareholder Engagement LOS ANGELES, Nov. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BL) (“BlackLine” or the “Company”) today issued the following statement: The Company and members of the Board of Directors actively meet with company stockholders on a regular basis. More recently, these meetings have included Engaged Capital with whom management and independent directors have met seven times in the past 12 months, including times when Engaged was and was not an investor in the Company. The Company remains open to constructive conversation with all stockho...
Myriad Genetics to Participate in Upcoming Investor Healthcare Confere...
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.The 37th Annual Piper Sandler Healthcare Conference with a fireside chat on Tuesday, Dec. 2, 2025, at 12:00 pm ET. The presentations will be available through live audio webcas...
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Heredit...
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs 100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced —the gold standard in germline testing—has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1 and guidelines from American Society of Clinical Oncology (ASCO). The...
BlackLine Announces Third Quarter Financial Results
BlackLine Announces Third Quarter Financial Results LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: BL), today announced financial results for the third quarter ended September 30, 2025. “BlackLine’s third-quarter results, with increasing revenue growth, solid margins, and strong free cash flow, demonstrate that our focus on improved execution is taking hold,” said Owen Ryan, CEO of BlackLine. “The deliberate changes we've made with our processes, technology, and people across our Product, Go-To-Market, and Operations teams are beginning to deliver the results we expect. As we ...
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 Nati...
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 44th Annual Conference. Myriad’s MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen and Foresight® Carrier Screen are among ...
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterat...
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Th...
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to Ge...
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner Faster initial remission and response, persistent benefit over six months SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that treatment informed by the GeneSight® test led to faster initial remission and response in patients with Major Depressive Disord...
Myriad Genetics to Release Third Quarter 2025 Financial Results on Nov...
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025 SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2025. A live webcast of the conference call can be a...
BlackLine Announces Date for Third Quarter 2025 Earnings Release and C...
BlackLine Announces Date for Third Quarter 2025 Earnings Release and Conference Call LOS ANGELES, Oct. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BL) announced today that it will release financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 6, 2025 followed by a conference call hosted by management at 2:00 p.m. PT / 5:00 p.m. ET. A live webcast and replay will be accessible on BlackLine’s investor relations website at . To access the conference call by phone, please register , and dial-in details will be provided. To avoid delays, we encoura...
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations SALT LAKE CITY, Oct. 14, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has added two genes, F8 and FXN, to the . “At Myriad Genetics, we carefully design the Foresight panel to prioritize clinical significance, selecting genes based on condition severity, prevalence, actionability, and guidelines,” sai...
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion...
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad’s advanced laboratory capabilities in the U.S. to support global test...
Myriad Genetics Announces Precise MRD Clinical Data Published in The L...
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a highlighting the performance of Myriad’s molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). One of the goals of this study was to determine whether patients with oligometastatic ccRCC could benefit from incorporating ultrasensitive MRD testing into t...
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can S...
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression Results published in the Journal of Clinical Psychopharmacology SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when ® Psychotropic test results were available to treating clinicia...
Myriad Genetics to Participate in Upcoming Investor Healthcare Confere...
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The Wells Fargo Healthcare Conference with a fireside chat on Thursday, Sept. 4 at 3:45pm ET.The Morgan Stanley Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 10 at 7:45am ET. Links to the live and archived webcasts of both presentations can be viewed at . About ...
BlackLine To Host Investor Session at BeyondTheBlack 2025
BlackLine To Host Investor Session at BeyondTheBlack 2025 LOS ANGELES, Aug. 26, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: BL), the future-ready platform for the Office of the CFO, today announced that it will host an investor session on Tuesday, September 9, 2025 in Las Vegas, Nevada at 1:30pm PT. The event will take place during BeyondTheBlack, the company’s annual customer conference. The webcast will be accessible on BlackLine’s investor relations website at . About BlackLine (Nasdaq: BL), the future-ready platform for the Office of the CFO, drives digital finance transformation by empow...
BlackLine Announces Participation in Upcoming Investor Conference
BlackLine Announces Participation in Upcoming Investor Conference LOS ANGELES, Aug. 20, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: BL) today announced that BlackLine’s management team will participate in the following upcoming investor conference: Citi’s 2025 Global TMT ConferenceWednesday, September 3, 2025Presentation time: 10:10 AM ETLocation: New York, NY The presentation webcast will be accessible on BlackLine’s investor relations website at . About BlackLine (Nasdaq: BL), the future-ready platform for the Office of the CFO, drives digital finance transformation by empowering organizat...
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Ben has been with Myriad for more than 13 years, joining the Company in December 2011 as assistant controller and advancing through leadership roles including vice president, corporate controller; senior vice president, accounting; and since 2022, chief financial officer, operations. Scot...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.